High and Varied Levels of Multidrug-Resistant Tuberculosis

Among isolates from patients with MDR-TB, 44% showed resistance to at least one second-line drug, and 7% were extensively resistant.

The prevalence of extensively drug-resistant tuberculosis (XDR-TB; i.e., resistant to at least isoniazid, rifampin, and ≥1 drug within each of the 2 most important groups of second-line anti-TB agents) is increasing as more patients with multidrug-resistant TB (MDR-TB; resistant to at least isoniazid and rifampin) are treated with second-line drugs. Of the 27 high MDR-TB burden countries, only 2 routinely test for susceptibility to second-line anti-TB agents. To assess the prevalence of and risk factors for resistance to these drugs, investigators conducted a prospective study involving consecutive adults with confirmed MDR pulmonary TB who started therapy between 2005 and 2008 in Estonia, Latvia, Peru, the Philippines, Russia, South Africa…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

High and Varied Levels of Multidrug-Resistant Tuberculosis

Topics

Reviewing Author